Evidence map›Paper›PMID 26713522›Full record

ArticleZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2015

[Combination of lapatinib with chlorogenic acid inhibits breast cancer metastasis by suppressing macrophage M2 polarization].

Jie-qiong Zhang, Zhang-ting Yao, Gui-kai Liang, Xi Chen, Hong-hai Wu, Lu Jin, Ling Ding

Open access · greenAbstract read
In one paragraph

Article in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jie-qiong ZhangCollege of Pharmaceutical Sciences, Zhejiang University, Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Hangzhou 310058, China.
Zhang-ting YaoCollege of Pharmaceutical Sciences, Zhejiang University, Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Hangzhou 310058, China.
Gui-kai LiangCollege of Pharmaceutical Sciences, Zhejiang University, Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Hangzhou 310058, China.
Xi ChenCollege of Pharmaceutical Sciences, Zhejiang University, Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Hangzhou 310058, China.
Hong-hai WuCollege of Pharmaceutical Sciences, Zhejiang University, Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Hangzhou 310058, China.
Lu JinDepartment of Neurology, the Second Affiliated Hospital Wenzhou Medical University, Wenzhou 325027, China.
Ling DingCollege of Pharmaceutical Sciences, Zhejiang University, Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, Hangzhou 310058, China.
Zhejiang University · CNWenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the effect of the combination of lapatinib with chlorogenic acid on metastasis of breast cancer in mouse model.

methodsThe classical macrophage M2 polarization model induced by interlukin13in vitro was adopted in the study. Flow cytometric analysis was performed to detect the expression of M2 marker CD206. The transcription of M2-associated genes was measured by RT-PCR. HE staining was used to analyze the metastatic nodes of breast cancer in lungs of MMTV-PyVT mice. Immunostaining analysis was used to detect the expression of related proteins in breast cancer.

resultsThe combination of lapatinib and chlorogenic acid inhibited the expression of CD206 induced by IL-13[(42.17%±2.59%) vs (61.15%±7.58%), P<0.05]. The combination more markedly suppressed expression of M2-associated gene Ym1 than lapatinib alone[(0.9±0.1) vs (1.8±0.0), P<0.05]. The combination of lapatinib and chlorogenic acid significantly reduced metastatic nodes in lung[P<0.05], and also significantly decreased the percentage of CD206(+) cells in breast cancer compared to controls[(6.08%±2.60%) vs(29.04%±5.86%), P<0.05].

conclusionThe combination of lapatinib and chlorogenic acid can effectively inhibit macrophage M2 polarization and metastasis of breast cancer.

Indexed as

AnimalsChlorogenic AcidFemaleLapatinibLung NeoplasmsMacrophagesMammary Neoplasms, ExperimentalMiceNeoplasm MetastasisQuinazolinesChlorogenic AcidLapatinibQuinazolines

Identifiers

PMID26713522
PMCPMC10400816
OpenAlexW2411038522

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.